Biomarker-guided antibiotic duration strategies using C-reactive protein and/or procalcitonin for neonatal sepsis: a

Aditya Hemendra Bhatt1, Ankur Patel2, Praful Bhambharoliya2

  • 1Department of Neonatology, Pramukhswami Medical College, Bhaikaka University, Karamsad, Gujarat, 388325, India.

Insights

Using biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) to guide antibiotic duration in neonatal sepsis can safely reduce antibiotic exposure. This approach lowers the average treatment length without increasing risks of treatment failure or death.

Area of Science:

  • Neonatal Medicine
  • Infectious Diseases
  • Biomarkers

Background:

  • Prolonged antibiotic use in neonates is linked to adverse outcomes and antimicrobial resistance.
  • Current neonatal sepsis protocols for antibiotic discontinuation are inconsistent.
  • Biomarkers like CRP and PCT show potential for guiding treatment duration.

Purpose of the Study:

  • To review evidence on using C-reactive protein (CRP) and/or procalcitonin (PCT) guided strategies for antibiotic duration in neonatal sepsis.
  • To summarize the impact of these biomarker-guided strategies on antibiotic exposure and patient safety.

Main Methods:

  • A systematic search of major databases (PubMed/MEDLINE, Embase, Web of Science, Cochrane Library) was conducted.
  • Studies published up to December 2023, involving neonates (0-28 days) with sepsis, using serial CRP and/or PCT for antibiotic discontinuation were included.
  • Data were screened and charted by two independent reviewers following Joanna Briggs Institute and PRISMA-ScR guidelines.

Main Results:

  • Fifteen studies (4755 neonates) were included, evaluating CRP, PCT, or combined biomarker-guided strategies.
  • Biomarker-guided care reduced mean antibiotic duration by 2.8 days (38.6%), from 7.3 to 4.5 days.
  • No significant increase in treatment failure or mortality was observed with biomarker-guided discontinuation.

Conclusions:

  • CRP- and/or PCT-guided strategies can effectively reduce antibiotic exposure in neonatal sepsis.
  • These approaches appear safe, without increasing treatment failure or mortality.
  • Standardized protocols and further research on cost-effectiveness and resistance are recommended, especially for preterm infants and in resource-limited settings.